Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer
Status: | Recruiting |
---|---|
Conditions: | Cancer, Cancer, Bladder Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/2/2018 |
Start Date: | April 2012 |
End Date: | April 2021 |
Contact: | Angie Smith, MD |
Email: | angela_smith@med.unc.edu |
Phone: | (919) 966-8217 |
PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy
The purpose of this study is to create a registry of older patients undergoing surgical
and/or medical treatment for bladder cancer. The registry will record side-effect and
outcomes related to the treatment using different surveys and biological measures.
and/or medical treatment for bladder cancer. The registry will record side-effect and
outcomes related to the treatment using different surveys and biological measures.
The primary purpose of this protocol is to create a registry of elderly patients with
high-risk invasive bladder cancer undergoing radical cystectomy with or without preoperative
chemotherapy.
Secondary objectives will include an exploration of the association between functional
status, surgical complications, and laboratory markers with complications and survival. In
addition, exploratory analyses may evaluate the association of expression of the senescence
marker p16INK4a and the morbidity and mortality associated with treatment.
Patients will be asked to complete a Geriatric Assessment (GA) and FACT-Bl serially over the
course of the study in order to evaluate their functional status and quality of life during
the course of treatment. Additionally, complications will be tracked in an inpatient and
outpatient setting using the Memorial Sloan Kettering Cancer Center (MSKCC) complications
grading system.
high-risk invasive bladder cancer undergoing radical cystectomy with or without preoperative
chemotherapy.
Secondary objectives will include an exploration of the association between functional
status, surgical complications, and laboratory markers with complications and survival. In
addition, exploratory analyses may evaluate the association of expression of the senescence
marker p16INK4a and the morbidity and mortality associated with treatment.
Patients will be asked to complete a Geriatric Assessment (GA) and FACT-Bl serially over the
course of the study in order to evaluate their functional status and quality of life during
the course of treatment. Additionally, complications will be tracked in an inpatient and
outpatient setting using the Memorial Sloan Kettering Cancer Center (MSKCC) complications
grading system.
Inclusion Criteria:
- Patients with a known pathologic diagnosis of lower tract urothelial carcinoma who are
eligible to undergo radical cystectomy with or without neoadjuvant chemotherapy for
definitive diagnosis and treatment.
- Signed, IRB approved written informed consent.
- Completion of baseline Geriatric Assessment
Exclusion Criteria:
- Inability to read and speak English
- Inability to comply with study for any other reason than language
- Dementia, altered mental status, or any psychiatric condition that would prohibit the
understanding or rendering of informed consent.
We found this trial at
1
site
Chapel Hill, North Carolina 27599
Principal Investigator: Angela Smith, MD
Phone: 919-966-0695
Click here to add this to my saved trials